계정 가입
email 로 로그인
email 로 가입
수신함을 확인하세요
VentiRx Pharmaceuticals
About
VentiRx Pharmaceuticals develops novel TLR8 therapeutics for the treatment of cancer, allergy, and respiratory and autoimmune diseases.
- 11 - 50
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $50.60M
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Jan 1, 2006
- Number Of Employee
- 11 - 50
- Operating Status
- Active
VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of medicines for the treatment of cancer, and respiratory and autoimmune diseases. The company focuses on the development of small molecule product candidates targeting toll-like receptor 8 (TLR8) agonists and antagonists. Its product pipeline comprises VTX-2337, a small molecule TLR8 agonist that stimulates myeloid dendritic cells and monocytes, and enhances natural killer cell responses for the treatment of solid tumors, ovarian and breast cancers, and NHL and SCHN; VTX-1463, a stand alone agent for the treatment of seasonal and perennial allergies; TLR8 antagonists for the treatment of autoimmune diseases; and multiple compounds that are treated as vaccine adjuvants. The company has a strategic agreement/collaboration with Celgene Corporation. VentiRx Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Seattle, Washington with operations in San Diego.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 23, 2014 | Series B | $50.60M | 1 | — | — | Detail |
| Jan 13, 2010 | Series A | $25M | 1 | — | — | Detail |
| Mar 6, 2007 | Series A | $26.60M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
ARCH Venture Partners
|
— | Series B |
